Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment

Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment

Malignant pleural mesothelioma (MPM) is strongly associated with occupational or environmental asbestos exposure and arises from neoplastic transformation of mesothelial cells in the pleural cavity. The only standard initial treatment for unresectable MPM is combination chemotherapy with cisplatin (...

Full description

Bibliographic Details
Main Authors: Yoshie Yoshikawa, Kozo Kuribayashi, Toshiyuki Minami, Masaki Ohmuraya, Takashi Kijima
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Oncology
Subjects:
chromatin modification
histone methylation
asbestos
mutations
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.554570/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.554570/full

Similar Items